nodes	percent_of_prediction	percent_of_DWPC	metapath
Apomorphine—HTR2A—arteriole—atherosclerosis	0.0124	0.158	CbGeAlD
Apomorphine—Libido increased—Niacin—atherosclerosis	0.0121	0.0339	CcSEcCtD
Apomorphine—HTR2A—vein—atherosclerosis	0.00737	0.0941	CbGeAlD
Apomorphine—Swelling—Simvastatin—atherosclerosis	0.00658	0.0185	CcSEcCtD
Apomorphine—HTR1B—artery—atherosclerosis	0.00624	0.0797	CbGeAlD
Apomorphine—Pain in extremity—Lovastatin—atherosclerosis	0.00621	0.0174	CcSEcCtD
Apomorphine—Pain in extremity—Ezetimibe—atherosclerosis	0.00609	0.0171	CcSEcCtD
Apomorphine—HTR1D—artery—atherosclerosis	0.00604	0.0771	CbGeAlD
Apomorphine—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00549	0.0154	CcSEcCtD
Apomorphine—Nasopharyngitis—Ezetimibe—atherosclerosis	0.00544	0.0153	CcSEcCtD
Apomorphine—Disturbance in sexual arousal—Niacin—atherosclerosis	0.00529	0.0149	CcSEcCtD
Apomorphine—HTR2A—hindlimb—atherosclerosis	0.0049	0.0625	CbGeAlD
Apomorphine—Orthostatic hypotension—Niacin—atherosclerosis	0.00487	0.0137	CcSEcCtD
Apomorphine—HTR1B—blood vessel—atherosclerosis	0.00486	0.0621	CbGeAlD
Apomorphine—HTR1D—blood vessel—atherosclerosis	0.00471	0.0601	CbGeAlD
Apomorphine—Nasopharyngitis—Pravastatin—atherosclerosis	0.00469	0.0132	CcSEcCtD
Apomorphine—Urinary tract infection—Lovastatin—atherosclerosis	0.00465	0.0131	CcSEcCtD
Apomorphine—Angina pectoris—Niacin—atherosclerosis	0.00449	0.0126	CcSEcCtD
Apomorphine—Mental disorder—Rosuvastatin—atherosclerosis	0.00444	0.0125	CcSEcCtD
Apomorphine—Sweating increased—Pravastatin—atherosclerosis	0.00442	0.0124	CcSEcCtD
Apomorphine—Angina pectoris—Pravastatin—atherosclerosis	0.00442	0.0124	CcSEcCtD
Apomorphine—HTR2A—appendage—atherosclerosis	0.0042	0.0536	CbGeAlD
Apomorphine—Flushing—Lovastatin—atherosclerosis	0.00398	0.0112	CcSEcCtD
Apomorphine—Urinary tract infection—Pravastatin—atherosclerosis	0.00393	0.011	CcSEcCtD
Apomorphine—Flushing—Ezetimibe—atherosclerosis	0.00391	0.011	CcSEcCtD
Apomorphine—Arthralgia—Rosuvastatin—atherosclerosis	0.00375	0.0105	CcSEcCtD
Apomorphine—Flushing—Simvastatin—atherosclerosis	0.00373	0.0105	CcSEcCtD
Apomorphine—Mental disorder—Ezetimibe—atherosclerosis	0.00369	0.0104	CcSEcCtD
Apomorphine—Confusional state—Rosuvastatin—atherosclerosis	0.00363	0.0102	CcSEcCtD
Apomorphine—Back pain—Lovastatin—atherosclerosis	0.00362	0.0102	CcSEcCtD
Apomorphine—Back pain—Ezetimibe—atherosclerosis	0.00355	0.00996	CcSEcCtD
Apomorphine—Mental disorder—Simvastatin—atherosclerosis	0.00352	0.00989	CcSEcCtD
Apomorphine—Flushing—Niacin—atherosclerosis	0.00342	0.00962	CcSEcCtD
Apomorphine—Flushing—Pravastatin—atherosclerosis	0.00337	0.00947	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00328	0.00921	CcSEcCtD
Apomorphine—Insomnia—Rosuvastatin—atherosclerosis	0.00326	0.00915	CcSEcCtD
Apomorphine—Arthralgia—Lovastatin—atherosclerosis	0.00318	0.00894	CcSEcCtD
Apomorphine—Chest pain—Lovastatin—atherosclerosis	0.00318	0.00894	CcSEcCtD
Apomorphine—Anxiety—Lovastatin—atherosclerosis	0.00317	0.00891	CcSEcCtD
Apomorphine—Arthralgia—Ezetimibe—atherosclerosis	0.00312	0.00877	CcSEcCtD
Apomorphine—Chest pain—Ezetimibe—atherosclerosis	0.00312	0.00877	CcSEcCtD
Apomorphine—Constipation—Rosuvastatin—atherosclerosis	0.00308	0.00865	CcSEcCtD
Apomorphine—Confusional state—Lovastatin—atherosclerosis	0.00308	0.00864	CcSEcCtD
Apomorphine—Confusional state—Ezetimibe—atherosclerosis	0.00302	0.00848	CcSEcCtD
Apomorphine—HTR2A—artery—atherosclerosis	0.003	0.0383	CbGeAlD
Apomorphine—Arthralgia—Simvastatin—atherosclerosis	0.00298	0.00836	CcSEcCtD
Apomorphine—Chest pain—Simvastatin—atherosclerosis	0.00298	0.00836	CcSEcCtD
Apomorphine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00297	0.00833	CcSEcCtD
Apomorphine—Anxiety—Simvastatin—atherosclerosis	0.00297	0.00833	CcSEcCtD
Apomorphine—Syncope—Niacin—atherosclerosis	0.00288	0.00809	CcSEcCtD
Apomorphine—Confusional state—Simvastatin—atherosclerosis	0.00288	0.00808	CcSEcCtD
Apomorphine—Oedema—Simvastatin—atherosclerosis	0.00285	0.00802	CcSEcCtD
Apomorphine—Loss of consciousness—Niacin—atherosclerosis	0.00282	0.00793	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00278	0.00781	CcSEcCtD
Apomorphine—Insomnia—Lovastatin—atherosclerosis	0.00276	0.00775	CcSEcCtD
Apomorphine—Arthralgia—Niacin—atherosclerosis	0.00273	0.00768	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00273	0.00766	CcSEcCtD
Apomorphine—Dyspnoea—Lovastatin—atherosclerosis	0.00272	0.00764	CcSEcCtD
Apomorphine—Insomnia—Ezetimibe—atherosclerosis	0.00271	0.0076	CcSEcCtD
Apomorphine—Chest pain—Pravastatin—atherosclerosis	0.00269	0.00756	CcSEcCtD
Apomorphine—Arthralgia—Pravastatin—atherosclerosis	0.00269	0.00756	CcSEcCtD
Apomorphine—Anxiety—Pravastatin—atherosclerosis	0.00268	0.00753	CcSEcCtD
Apomorphine—Dyspnoea—Ezetimibe—atherosclerosis	0.00267	0.00749	CcSEcCtD
Apomorphine—Fatigue—Lovastatin—atherosclerosis	0.00263	0.00739	CcSEcCtD
Apomorphine—Oedema—Niacin—atherosclerosis	0.00262	0.00736	CcSEcCtD
Apomorphine—Constipation—Lovastatin—atherosclerosis	0.00261	0.00733	CcSEcCtD
Apomorphine—Confusional state—Pravastatin—atherosclerosis	0.0026	0.00731	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.0026	0.0073	CcSEcCtD
Apomorphine—Asthenia—Rosuvastatin—atherosclerosis	0.00258	0.00726	CcSEcCtD
Apomorphine—Insomnia—Simvastatin—atherosclerosis	0.00258	0.00725	CcSEcCtD
Apomorphine—Oedema—Pravastatin—atherosclerosis	0.00258	0.00725	CcSEcCtD
Apomorphine—Fatigue—Ezetimibe—atherosclerosis	0.00258	0.00725	CcSEcCtD
Apomorphine—Shock—Niacin—atherosclerosis	0.00258	0.00724	CcSEcCtD
Apomorphine—Constipation—Ezetimibe—atherosclerosis	0.00256	0.00719	CcSEcCtD
Apomorphine—Pruritus—Rosuvastatin—atherosclerosis	0.00255	0.00716	CcSEcCtD
Apomorphine—Dyspnoea—Simvastatin—atherosclerosis	0.00254	0.00715	CcSEcCtD
Apomorphine—HTR2A—endothelium—atherosclerosis	0.00254	0.0324	CbGeAlD
Apomorphine—Hyperhidrosis—Niacin—atherosclerosis	0.00253	0.00712	CcSEcCtD
Apomorphine—Feeling abnormal—Lovastatin—atherosclerosis	0.00251	0.00706	CcSEcCtD
Apomorphine—Hyperhidrosis—Pravastatin—atherosclerosis	0.00249	0.00701	CcSEcCtD
Apomorphine—Feeling abnormal—Ezetimibe—atherosclerosis	0.00247	0.00693	CcSEcCtD
Apomorphine—Diarrhoea—Rosuvastatin—atherosclerosis	0.00246	0.00692	CcSEcCtD
Apomorphine—Fatigue—Simvastatin—atherosclerosis	0.00246	0.00691	CcSEcCtD
Apomorphine—Hypotension—Niacin—atherosclerosis	0.00245	0.00688	CcSEcCtD
Apomorphine—Constipation—Simvastatin—atherosclerosis	0.00244	0.00686	CcSEcCtD
Apomorphine—HTR1D—connective tissue—atherosclerosis	0.00241	0.0308	CbGeAlD
Apomorphine—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00239	0.00671	CcSEcCtD
Apomorphine—Dizziness—Rosuvastatin—atherosclerosis	0.00238	0.00669	CcSEcCtD
Apomorphine—Insomnia—Niacin—atherosclerosis	0.00237	0.00666	CcSEcCtD
Apomorphine—Feeling abnormal—Simvastatin—atherosclerosis	0.00235	0.00661	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00235	0.0066	CcSEcCtD
Apomorphine—HTR2A—blood vessel—atherosclerosis	0.00234	0.0299	CbGeAlD
Apomorphine—Dyspnoea—Niacin—atherosclerosis	0.00234	0.00656	CcSEcCtD
Apomorphine—Insomnia—Pravastatin—atherosclerosis	0.00233	0.00656	CcSEcCtD
Apomorphine—Somnolence—Niacin—atherosclerosis	0.00233	0.00654	CcSEcCtD
Apomorphine—Dyspnoea—Pravastatin—atherosclerosis	0.0023	0.00646	CcSEcCtD
Apomorphine—Headache—Rosuvastatin—atherosclerosis	0.00225	0.00634	CcSEcCtD
Apomorphine—Fatigue—Pravastatin—atherosclerosis	0.00222	0.00625	CcSEcCtD
Apomorphine—Constipation—Pravastatin—atherosclerosis	0.00221	0.0062	CcSEcCtD
Apomorphine—Asthenia—Lovastatin—atherosclerosis	0.00219	0.00615	CcSEcCtD
Apomorphine—HTR1B—cardiovascular system—atherosclerosis	0.00217	0.0277	CbGeAlD
Apomorphine—Pruritus—Lovastatin—atherosclerosis	0.00216	0.00606	CcSEcCtD
Apomorphine—Asthenia—Ezetimibe—atherosclerosis	0.00215	0.00603	CcSEcCtD
Apomorphine—Nausea—Rosuvastatin—atherosclerosis	0.00214	0.00601	CcSEcCtD
Apomorphine—Feeling abnormal—Pravastatin—atherosclerosis	0.00213	0.00597	CcSEcCtD
Apomorphine—Pruritus—Ezetimibe—atherosclerosis	0.00212	0.00595	CcSEcCtD
Apomorphine—HTR1D—cardiovascular system—atherosclerosis	0.0021	0.0268	CbGeAlD
Apomorphine—Diarrhoea—Lovastatin—atherosclerosis	0.00209	0.00586	CcSEcCtD
Apomorphine—Asthenia—Simvastatin—atherosclerosis	0.00205	0.00575	CcSEcCtD
Apomorphine—Diarrhoea—Ezetimibe—atherosclerosis	0.00205	0.00575	CcSEcCtD
Apomorphine—Pruritus—Simvastatin—atherosclerosis	0.00202	0.00567	CcSEcCtD
Apomorphine—Dizziness—Lovastatin—atherosclerosis	0.00202	0.00567	CcSEcCtD
Apomorphine—Dizziness—Ezetimibe—atherosclerosis	0.00198	0.00556	CcSEcCtD
Apomorphine—HTR2B—cardiovascular system—atherosclerosis	0.00195	0.0249	CbGeAlD
Apomorphine—Diarrhoea—Simvastatin—atherosclerosis	0.00195	0.00549	CcSEcCtD
Apomorphine—Vomiting—Lovastatin—atherosclerosis	0.00194	0.00545	CcSEcCtD
Apomorphine—Headache—Lovastatin—atherosclerosis	0.00191	0.00537	CcSEcCtD
Apomorphine—Vomiting—Ezetimibe—atherosclerosis	0.0019	0.00534	CcSEcCtD
Apomorphine—Dizziness—Simvastatin—atherosclerosis	0.00189	0.0053	CcSEcCtD
Apomorphine—Asthenia—Niacin—atherosclerosis	0.00188	0.00528	CcSEcCtD
Apomorphine—Headache—Ezetimibe—atherosclerosis	0.00187	0.00527	CcSEcCtD
Apomorphine—Pruritus—Niacin—atherosclerosis	0.00185	0.00521	CcSEcCtD
Apomorphine—Asthenia—Pravastatin—atherosclerosis	0.00185	0.0052	CcSEcCtD
Apomorphine—Pruritus—Pravastatin—atherosclerosis	0.00182	0.00513	CcSEcCtD
Apomorphine—Vomiting—Simvastatin—atherosclerosis	0.00181	0.0051	CcSEcCtD
Apomorphine—Nausea—Lovastatin—atherosclerosis	0.00181	0.00509	CcSEcCtD
Apomorphine—Diarrhoea—Niacin—atherosclerosis	0.00179	0.00504	CcSEcCtD
Apomorphine—Headache—Simvastatin—atherosclerosis	0.00179	0.00502	CcSEcCtD
Apomorphine—Nausea—Ezetimibe—atherosclerosis	0.00178	0.00499	CcSEcCtD
Apomorphine—Diarrhoea—Pravastatin—atherosclerosis	0.00176	0.00496	CcSEcCtD
Apomorphine—HTR1A—cardiovascular system—atherosclerosis	0.00175	0.0223	CbGeAlD
Apomorphine—Dizziness—Niacin—atherosclerosis	0.00173	0.00487	CcSEcCtD
Apomorphine—HTR2B—adipose tissue—atherosclerosis	0.00172	0.022	CbGeAlD
Apomorphine—Dizziness—Pravastatin—atherosclerosis	0.00171	0.00479	CcSEcCtD
Apomorphine—Nausea—Simvastatin—atherosclerosis	0.00169	0.00476	CcSEcCtD
Apomorphine—Vomiting—Niacin—atherosclerosis	0.00167	0.00468	CcSEcCtD
Apomorphine—Headache—Niacin—atherosclerosis	0.00164	0.00461	CcSEcCtD
Apomorphine—Vomiting—Pravastatin—atherosclerosis	0.00164	0.00461	CcSEcCtD
Apomorphine—Headache—Pravastatin—atherosclerosis	0.00162	0.00454	CcSEcCtD
Apomorphine—Nausea—Niacin—atherosclerosis	0.00156	0.00437	CcSEcCtD
Apomorphine—Nausea—Pravastatin—atherosclerosis	0.00153	0.00431	CcSEcCtD
Apomorphine—ADRA2A—connective tissue—atherosclerosis	0.00141	0.018	CbGeAlD
Apomorphine—ADRA2C—adipose tissue—atherosclerosis	0.00136	0.0173	CbGeAlD
Apomorphine—HTR2A—connective tissue—atherosclerosis	0.0012	0.0153	CbGeAlD
Apomorphine—ADRA2A—adipose tissue—atherosclerosis	0.00108	0.0138	CbGeAlD
Apomorphine—HTR2A—cardiovascular system—atherosclerosis	0.00104	0.0133	CbGeAlD
Apomorphine—ADRA2C—liver—atherosclerosis	0.000951	0.0121	CbGeAlD
Apomorphine—HTR2A—liver—atherosclerosis	0.000645	0.00824	CbGeAlD
Apomorphine—DRD4—GPCR downstream signaling—AKT1—atherosclerosis	2.66e-05	4.69e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—F2—atherosclerosis	2.65e-05	4.69e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—INS—atherosclerosis	2.65e-05	4.68e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—IGF1—atherosclerosis	2.65e-05	4.68e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—ESR1—atherosclerosis	2.64e-05	4.67e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—MAPK3—atherosclerosis	2.64e-05	4.66e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—IGF1—atherosclerosis	2.63e-05	4.65e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	2.63e-05	4.65e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—CXCL8—atherosclerosis	2.62e-05	4.64e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PPARG—atherosclerosis	2.62e-05	4.63e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling by GPCR—IL6—atherosclerosis	2.61e-05	4.62e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—F2—atherosclerosis	2.61e-05	4.61e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—INS—atherosclerosis	2.61e-05	4.6e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CCL2—atherosclerosis	2.6e-05	4.6e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—SERPINE1—atherosclerosis	2.6e-05	4.6e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—MMP9—atherosclerosis	2.58e-05	4.56e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—INS—atherosclerosis	2.57e-05	4.55e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—AGT—atherosclerosis	2.57e-05	4.54e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CCL2—atherosclerosis	2.56e-05	4.53e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—IGF1—atherosclerosis	2.56e-05	4.53e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Hemostasis—AKT1—atherosclerosis	2.56e-05	4.52e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—NFKB1—atherosclerosis	2.55e-05	4.51e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—PTGS2—atherosclerosis	2.54e-05	4.49e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PIK3CG—atherosclerosis	2.54e-05	4.48e-05	CbGpPWpGaD
Apomorphine—HTR2B—GPCR downstream signaling—AKT1—atherosclerosis	2.54e-05	4.48e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—MMP9—atherosclerosis	2.53e-05	4.47e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—IGF1—atherosclerosis	2.52e-05	4.45e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—LEP—atherosclerosis	2.52e-05	4.45e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—APOE—atherosclerosis	2.52e-05	4.45e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	2.51e-05	4.44e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—MAPK8—atherosclerosis	2.51e-05	4.44e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling by GPCR—AKT1—atherosclerosis	2.5e-05	4.42e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	2.5e-05	4.42e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—NFKB1—atherosclerosis	2.5e-05	4.42e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	2.5e-05	4.41e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling by GPCR—IL6—atherosclerosis	2.5e-05	4.41e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	2.49e-05	4.41e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	2.49e-05	4.4e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—MMP9—atherosclerosis	2.49e-05	4.39e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—NOS3—atherosclerosis	2.49e-05	4.39e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—CXCL8—atherosclerosis	2.47e-05	4.37e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—NFKB1—atherosclerosis	2.46e-05	4.35e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—MAPK8—atherosclerosis	2.46e-05	4.34e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling by GPCR—AKT1—atherosclerosis	2.45e-05	4.33e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—CXCL8—atherosclerosis	2.44e-05	4.32e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—CXCL8—atherosclerosis	2.44e-05	4.32e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—SERPINE1—atherosclerosis	2.43e-05	4.3e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	2.43e-05	4.3e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—MAPK8—atherosclerosis	2.42e-05	4.27e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling by GPCR—AKT1—atherosclerosis	2.41e-05	4.26e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	2.4e-05	4.25e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—INS—atherosclerosis	2.4e-05	4.25e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—NOS3—atherosclerosis	2.4e-05	4.24e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—SERPINE1—atherosclerosis	2.39e-05	4.23e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	2.39e-05	4.23e-05	CbGpPWpGaD
Apomorphine—DRD1—GPCR downstream signaling—AKT1—atherosclerosis	2.39e-05	4.23e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—NOS3—atherosclerosis	2.39e-05	4.22e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—F2—atherosclerosis	2.37e-05	4.2e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—MMP9—atherosclerosis	2.37e-05	4.2e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—INS—atherosclerosis	2.36e-05	4.18e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CCL2—atherosclerosis	2.36e-05	4.18e-05	CbGpPWpGaD
Apomorphine—DRD3—GPCR downstream signaling—AKT1—atherosclerosis	2.36e-05	4.17e-05	CbGpPWpGaD
Apomorphine—ADRA1D—GPCR downstream signaling—AKT1—atherosclerosis	2.36e-05	4.17e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—ALB—atherosclerosis	2.36e-05	4.17e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling by GPCR—IL6—atherosclerosis	2.35e-05	4.16e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	2.35e-05	4.15e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CCL2—atherosclerosis	2.33e-05	4.11e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—IGF1—atherosclerosis	2.32e-05	4.11e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling by GPCR—IL6—atherosclerosis	2.32e-05	4.1e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling by GPCR—IL6—atherosclerosis	2.32e-05	4.1e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—NOS3—atherosclerosis	2.32e-05	4.1e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	2.32e-05	4.1e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	2.31e-05	4.08e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	2.3e-05	4.07e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—STAT3—atherosclerosis	2.29e-05	4.06e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—IGF1—atherosclerosis	2.29e-05	4.04e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—NOS3—atherosclerosis	2.28e-05	4.04e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	2.27e-05	4.01e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	2.27e-05	4.01e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—NOS3—atherosclerosis	2.26e-05	3.99e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—STAT3—atherosclerosis	2.25e-05	3.97e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—MMP9—atherosclerosis	2.24e-05	3.96e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—VEGFA—atherosclerosis	2.23e-05	3.95e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—NFKB1—atherosclerosis	2.21e-05	3.91e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—STAT3—atherosclerosis	2.21e-05	3.91e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—MMP9—atherosclerosis	2.21e-05	3.9e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—MMP9—atherosclerosis	2.21e-05	3.9e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	2.21e-05	3.9e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—CXCL8—atherosclerosis	2.2e-05	3.9e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	2.19e-05	3.87e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—NFKB1—atherosclerosis	2.19e-05	3.86e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—NFKB1—atherosclerosis	2.19e-05	3.86e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—MAPK8—atherosclerosis	2.18e-05	3.85e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	2.18e-05	3.85e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling by GPCR—AKT1—atherosclerosis	2.17e-05	3.84e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	2.17e-05	3.84e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—INS—atherosclerosis	2.15e-05	3.8e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—MAPK8—atherosclerosis	2.15e-05	3.8e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—MAPK8—atherosclerosis	2.15e-05	3.8e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	2.15e-05	3.79e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling by GPCR—AKT1—atherosclerosis	2.14e-05	3.79e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling by GPCR—AKT1—atherosclerosis	2.14e-05	3.79e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	2.13e-05	3.77e-05	CbGpPWpGaD
Apomorphine—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	2.13e-05	3.76e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	2.13e-05	3.76e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	2.13e-05	3.76e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	2.12e-05	3.74e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	2.12e-05	3.74e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—MAPK3—atherosclerosis	2.11e-05	3.73e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—STAT3—atherosclerosis	2.11e-05	3.73e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—NOS3—atherosclerosis	2.11e-05	3.72e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	2.1e-05	3.71e-05	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—IL6—atherosclerosis	2.09e-05	3.7e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	2.08e-05	3.68e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	2.08e-05	3.68e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—NOS3—atherosclerosis	2.07e-05	3.66e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PTGS2—atherosclerosis	2.06e-05	3.65e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	2.06e-05	3.64e-05	CbGpPWpGaD
Apomorphine—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	2.06e-05	3.63e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—TGFB1—atherosclerosis	2.05e-05	3.62e-05	CbGpPWpGaD
Apomorphine—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	2.05e-05	3.61e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	2.03e-05	3.58e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling by GPCR—IL6—atherosclerosis	2.02e-05	3.58e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	2.02e-05	3.56e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling by GPCR—IL6—atherosclerosis	2.01e-05	3.56e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—VEGFA—atherosclerosis	2.01e-05	3.55e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	1.99e-05	3.52e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—STAT3—atherosclerosis	1.99e-05	3.52e-05	CbGpPWpGaD
Apomorphine—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	1.99e-05	3.52e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—VEGFA—atherosclerosis	1.98e-05	3.51e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—VEGFA—atherosclerosis	1.98e-05	3.51e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	1.98e-05	3.49e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	1.97e-05	3.49e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—STAT3—atherosclerosis	1.96e-05	3.47e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—STAT3—atherosclerosis	1.96e-05	3.47e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	1.96e-05	3.46e-05	CbGpPWpGaD
Apomorphine—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	1.96e-05	3.46e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	1.96e-05	3.46e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	1.94e-05	3.43e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	1.93e-05	3.42e-05	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—AKT1—atherosclerosis	1.93e-05	3.41e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	1.93e-05	3.41e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MMP9—atherosclerosis	1.92e-05	3.4e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MMP9—atherosclerosis	1.91e-05	3.38e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	1.9e-05	3.37e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—MAPK3—atherosclerosis	1.9e-05	3.36e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	1.89e-05	3.35e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	1.89e-05	3.33e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—MAPK3—atherosclerosis	1.88e-05	3.32e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—MAPK3—atherosclerosis	1.88e-05	3.32e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	1.87e-05	3.31e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CXCL8—atherosclerosis	1.87e-05	3.3e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	1.87e-05	3.3e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	1.86e-05	3.29e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	1.86e-05	3.29e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	1.86e-05	3.28e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—TGFB1—atherosclerosis	1.84e-05	3.26e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	1.84e-05	3.26e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	1.84e-05	3.25e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	1.83e-05	3.24e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—TGFB1—atherosclerosis	1.82e-05	3.22e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—TGFB1—atherosclerosis	1.82e-05	3.22e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	1.81e-05	3.21e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	1.81e-05	3.2e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	1.81e-05	3.19e-05	CbGpPWpGaD
Apomorphine—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	1.8e-05	3.19e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	1.79e-05	3.16e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	1.78e-05	3.15e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	1.78e-05	3.14e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—IL6—atherosclerosis	1.78e-05	3.14e-05	CbGpPWpGaD
Apomorphine—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	1.78e-05	3.14e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	1.77e-05	3.13e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—IL6—atherosclerosis	1.75e-05	3.09e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	1.73e-05	3.05e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	1.72e-05	3.04e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—STAT3—atherosclerosis	1.71e-05	3.02e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—STAT3—atherosclerosis	1.7e-05	3.01e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	1.69e-05	2.99e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MMP9—atherosclerosis	1.69e-05	2.99e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	1.67e-05	2.96e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	1.67e-05	2.96e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—NFKB1—atherosclerosis	1.67e-05	2.96e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MMP9—atherosclerosis	1.66e-05	2.94e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	1.66e-05	2.93e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	1.65e-05	2.91e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	1.65e-05	2.91e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MAPK8—atherosclerosis	1.64e-05	2.91e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	1.64e-05	2.9e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—AKT1—atherosclerosis	1.64e-05	2.9e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	1.64e-05	2.89e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	1.63e-05	2.88e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	1.63e-05	2.88e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	1.62e-05	2.86e-05	CbGpPWpGaD
Apomorphine—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	1.62e-05	2.86e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	1.61e-05	2.85e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—IL6—atherosclerosis	1.6e-05	2.83e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	1.59e-05	2.81e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	1.59e-05	2.8e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	1.58e-05	2.8e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	1.58e-05	2.79e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—IL6—atherosclerosis	1.57e-05	2.77e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	1.56e-05	2.75e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—IL6—atherosclerosis	1.54e-05	2.73e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	1.54e-05	2.71e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—VEGFA—atherosclerosis	1.52e-05	2.68e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	1.51e-05	2.67e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	1.51e-05	2.67e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—STAT3—atherosclerosis	1.5e-05	2.66e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	1.5e-05	2.65e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	1.49e-05	2.64e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—AKT1—atherosclerosis	1.48e-05	2.61e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—STAT3—atherosclerosis	1.48e-05	2.61e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—IL6—atherosclerosis	1.47e-05	2.61e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	1.47e-05	2.6e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	1.47e-05	2.59e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—AKT1—atherosclerosis	1.45e-05	2.56e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MAPK3—atherosclerosis	1.44e-05	2.54e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—AKT1—atherosclerosis	1.42e-05	2.52e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	1.41e-05	2.5e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—TGFB1—atherosclerosis	1.39e-05	2.46e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—IL6—atherosclerosis	1.39e-05	2.46e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—IL6—atherosclerosis	1.37e-05	2.42e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—IL6—atherosclerosis	1.37e-05	2.42e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	1.37e-05	2.42e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—AKT1—atherosclerosis	1.36e-05	2.4e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	1.36e-05	2.4e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	1.35e-05	2.38e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	1.29e-05	2.27e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—AKT1—atherosclerosis	1.28e-05	2.27e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—AKT1—atherosclerosis	1.28e-05	2.26e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—AKT1—atherosclerosis	1.27e-05	2.24e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—AKT1—atherosclerosis	1.27e-05	2.24e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	1.25e-05	2.2e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—IL6—atherosclerosis	1.24e-05	2.19e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—IL6—atherosclerosis	1.2e-05	2.11e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—IL6—atherosclerosis	1.19e-05	2.1e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—IL6—atherosclerosis	1.16e-05	2.04e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	1.14e-05	2.02e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—IL6—atherosclerosis	1.14e-05	2.01e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.1e-05	1.95e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—AKT1—atherosclerosis	1.1e-05	1.94e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	1.07e-05	1.89e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	1.05e-05	1.86e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—IL6—atherosclerosis	1.05e-05	1.86e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—AKT1—atherosclerosis	1.04e-05	1.83e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—IL6—atherosclerosis	1.03e-05	1.83e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—AKT1—atherosclerosis	9.68e-06	1.71e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—AKT1—atherosclerosis	9.53e-06	1.68e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—IL6—atherosclerosis	9.4e-06	1.66e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	8.67e-06	1.53e-05	CbGpPWpGaD
